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The DiGeorge syndrome (DGS) is a developmental 
defect of the third and fourth pharyngeal pouches, 
which is associated with congenital heart defects, 
hypoparathyroidism, cell-mediated immunodeficiency, 
velo-pharyngeal insufficiency and craniofacial 
dysmorphism. The aetiological factor in a great 
majority of DGS cases is monosomy for the 
chromosomal region 22qll. To analyze DGS at the 
molecular level, a new molecular probe (DGCR680) 
encompassing the ADU balanced translocation 
breakpoint was prepared. When 13 Korean patients 
with DGS-type congenital heart disease were analyzed 
with this probe, 9 turned out to have a deletion at this 
locus, and all of them except one exhibited a typical 
facial dysmorphism associated DGS. Though only 9 
independent patients were detected." to have a deletion 
at the locus using the commercial probe N25 (D22S75), 
which maps at about 160 kb from the ADU breakpoint 
to the telomeric end, results from fluorescence in situ 
hybridization revealed a deletion in all cases tested at 
this locus. Two patients who had a deletion at the locus 
D22S75 but not at DGCR680 did not exhibit any DGS-
type facial abnormalities. This result implies that the 
680 bp probe covering the ADU translocation 
breakpoint might be a candidate for a molecular 
marker that can distinguish a specific phenotype, such 
as facial features associated with the DiGeorge 
syndrome. This study also suggested that systematic 
approaches with several small DNA probes along the 
DGCR could help to dissect the complex phenotypes 
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associated with the DiGeorge syndrome, such as 
cardiac defects, abnormal faces, thymic hypoplasia, 
cleft palate, and hypocalcemia, etc. 
Keywords: Conotruncal Anomaly Facial Syndrome 
(CTAFS); Diagnosis; DiGeorge Syndrome. 
Introduction 
The DiGeorge syndrome (DGS) is a developmental field 
defect of the third and fo urth pharyngeal pouches which 
assoc iates hypoplas ia or apl as ia of the thymus and 
parathyroids, conotruncal cardiac malformations and facial 
abnormalities (Muller et aI., 1988) . Although the aetiology 
of DGS is heterogeneous, about 90% of the patients exhibit 
monosomy at the 22qll chromosomal region. Such 
monoso my is know n to be associa ted with oth er 
phenotypes including the velocardiofacial (Shprintzen) 
syndrome (VCFS), conotruncal anomaly fac ial syndrome 
(CTAFS ), and sporadi c or familial cardiac defec ts, 
implying that these represent variants of the same disorder 
generated by the common cause (Demczuk and Aurias, 
1995). Therefore, the defects caused by the deletions in 
chromosome 22 are all represented by the acronym 
CATCH22, which stands for cardiac defects, Abnormal 
faces, Thymic hypoplasia, Cleft palate, and Hypocalcemia 
(Wilson et aI. , 1993). 
Cy toge neti c as we ll as hi gh resolution bandin g 
techniques have revealed that most patients with DGS have 
Abbreviations: CTAFS, conotruncal anomaly facial syndrome; 
DGS, DiGeorge syndrome; VCFS, velocardiofacial (Shprintzen) 
syndrome. 
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unbalanced translocation involving chromosome 22, or 
interstiti al deletions within this chromosome. An anal ysis 
of numerous patients with diffe rent dele tion endpoints 
showed th a t th ere is a reg io n, so-calle d the DOeR 
(DiOeorge syndrome critical regio n), which is about 
1.5 M b, is deleted in the majority of the patients. The 
extent of the deletion, however, does not seem to correlate 
with the severity of clinical fea tures, implying that one or 
perhaps a few genes playa major role in its pathogenesis. 
M o reover, a ba lanced trans loca ti o n w hich di s rupte d 
sequences within the shortest region of the deletion overlap 
for the DIOeorge syndrome has been reported in one 
patient - AD U (46,XX,t(2;22)(qI4 .I ;qI1.1 ) - and the 
same translocation was present in her mother (YDU), who 
was mildl y affected (Aug usseau et ai., 1986). These 
f indings s t ro ng ly sugges ted tha t th e 22qll de le tion 
phenotype could be determined by a single gene. The DOS 
phenotype in AD U and YDU has made this balanced 
translocati on point the target for the positional cloning 
approaches in the hope of isolating the critical gene(s) 
respons ible for DOS . 
Thus far, several cDNA and molecular probes for 
diagnosis have been isolated (Funke et ai. , 1997; 1998; 
Ooldmuntz et ai. , 1996; Halford et ai. , 1993; Lindsey 
et ai. , 1996; M cKie et ai. , 1997; Sutherl and et ai. , 1996; 
Wadey et a!. , 1995). However, none of them encompasses 
the ADU breakpoint except rnex40, DOeR3 (Budarf et ai. , 
1995) and DOeR5 (Sutherland et ai. , 1996). Since both 
DOe R3 and DOeRS have not been proven to have protein 
encoding potential , we attempted to isolate a real transcript 
using a new DNA probe which covers the ADU breakpoint 
based on previously publi shed sequences (Budarf et ai. , 
1995). During the course of this study, we found that the 
probe we generated was an efficient molecular marker for 
diagnosing DOS, since it hybridized with an unexpected 
band which could be used as an internal control for dosage 
analysis . In thi s study, 13 Korean patients having the DOS-
type congenital heart di sease were anal yzed with the 
generated probe, and compared with the fluorescence in 
situ hybridization data prepared with commercia l probe 
N25 (D22S75), which maps at about 160 kb from the ADU 
breakpoint toward the te lomeric end . 
Materials and Methods 
Patient selection and clinical evaluation Thirteen Korean 
patients with DGS-type congenital heart disease (CHD) were 
selected for molecular studies (Ten patients were evaluated at the 
Seoul National University College of Medicine, and three were 
evaluated at the Sejong Hospital in Seoul , Korea). Eight out of 
the 13 patients studied had the characteristic fac ial features for 
DGS (Table 1), consisting of hypertelorism, anti mongoloid slant, 
bloated eyelids, recurrent otitis medi a, prominent nose with 
squared nasal roof, deficient malar area, retruded mandible, short 
philtrum, small mouth, A-shaped mouth, nasal voice, high arched 
palate, narrow palpebral fissures, asymmetric low-set malformed 
ears and long face. 
DNA probes Two primers (5 ' primer, BI: 5 '-GGCTCT 
AGGGATCAGCACAGCCAGC, and 3' primer, B2: 5' -
CTCCCATTTTACAGTAGGAGGCTGG) were designed to 
be located at both the 5' and 3' sides of the ADU balanced 
translocation point based on the nucleotide sequences around the 
breakpoint (Budarf et aI. , 1995), and were sy nthes ized 
chemically. The 680 bp fragment of DGCR680 was obtained by 
amplification of the human genomic DNA using Bland B2 as 
PCR primers, and then it was used as a DNA probe after 
subcloning it into the pBluescript SK (pDGCR680) followed by 
sequencing. 
Southern analysis The genomic DNA purifi ed from th e 
leukocytes of 13 patients and four normal controls was digested 
with HindIII , and then Southern hybridi zation was conducted 
according to the standard procedure with 32P-labelled DGCR680 
as a probe. In brief, all prehybridizati on and hybridizati on 
reactions were carried out in 0.5 M Sodium phosphate buffer 
(pH 7.2) with 7% SDS, I mM EDTA and 1% BSA at 55°C 
(Sambrook et at. , 1989). To decrease the background generated 
by the human repetiti ve sequences , membranes we re 
prehybridized with sonicated human placental DNA. Membranes 
were then washed with 2X SSC (0.3 M NaC!, 30 mM sodium 
citrate, pH 7.0), I X SSC and 0.2X SSC containing 0.1 % (w/v) 
SDS at 65°C for 30 min each. 
Dosage analysis To determine the copy number, a quantitati ve 
analysis of Southern blot bands was performed. The DGCR680 
probe recognized an 18 kb band in the 22qll chromosomal 
reg ion and a 16 kb HindIII frag ment as well. Hybridization 
signals on the filter were quantitated by a Phosphor-Imager S425 
system (Molec ul ar Dynami cs), equipped with ImageQuant 
software (version 3.3) which measured the radiation energy 
directly. The signal strengths were normalized and the ratios were 
calcul ated by fo llowing the basic protocol published prev iously 
(Driscoll et at., 1992). In brief, the standard hybridizati on signals 
were calculated by taking the ratio of the radiation energy emitted 
by the 18 kb fragment to that of the control 16 kb fragment. The 
copy number was designated as twice the mean of the ratios of 
standard signals. It was assumed that one or two copies of a locus 
were present. Values less than 1.5 were defined as hemi zygosity, 
whereas values greater than 1.5 were not. All studies were 
performed in triplicates. 
FISH analysis Human metaphase chromosomes were prepared 
from lymphoid cell lines and/or peripheral blood by standard 
methods. The hybridization mixture containing the digoxigenin-
labeled D22S75 (N25) DGCR probe, along with the D22S39 
control probe (Oncor, Gaithersburg, MD, USA) was placed on the 
denatured chromosome slides fo ll owing the manufac turer 's 
instructions. After overnight hybridIzation at 37°C, the slides 
were incubated with anti-digoxigenin fluorescein in I X PBD/ 
5%BSA at 37°C for I h and rinsed. For amplification, the slides 
were treated with rabbit anti-sheep antibodies at 37°C for 30 min 
and incubated with FITC-rabbit antibody at 37°C for 30 min. The 
chromosomes were then counterstained with propidium iodide in 
an antifade solution. 
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Table 1. Summary of molecular analysis and clinical findings of DGS patients. 
Patient Sex · Age Types of Typical Others Molecular Deletionb 
No. (yr.) cardiac faces Dosage FISH 
anomaly" analysis 
M 0.2 TOF, + Mother + + 
MAPCA (TOF) 
2 F 2.0 PA NT 
3 F 7.0 TOF, + + NT 
MAPCA 
4 M 13.0 TOF + + 
5 F 1.0 TOF +/- Mother NT 
(CATCH22 
questionable) 
6 M 2.0 TOF, PDA, + + + 
MAPCA 
7 F 2.6 TOF, + + + 
MAPCA 
8 F 0.7 TOF, +/- + 
MAPCA 
9 F 1.8 ASD · + 
10 M 0.6 TOF, + + + 
MAPCA 
II M 17.0 TOF, + Cleft palate, + + 
MAPCA Maternal aunt 
(CHD) 
12 M 3.0 TOF, + + + 
MAPCA 
13 M 5.0 TOF, + + NT 
MAPCA 
a tertralogy of fallot (TOF), artrial septal defect (ASD), multiple anomalous pulmonary collateral arteries (MAPCA), patent ductus 
arteriosus (PDA), pulmonary atresia (PA). 
b Dosage analysis (+: deleted! - : not deleted), NT (not tested). 
Results and Discussion 
The most dramatic and clinically important issue for the 
genetic origin of congenital heart disease has been the 
recent discovery of the association of conotruncal defects 
with the deletion within the chromosomal region, 22q 11. 
The acronym CATCH22 (Cardiac defects, Abnormal faces, 
Thymic hypoplasia, Cleft palate, and Hypocalcemia from 
deletions in chromosome 22) was coined to encompass the 
spectrum of clinical manifestations in patients with 
deletions in this locus (Wilson et aI., 1993). DOS, YCFS, 
and CTAFS belong to this syndrome having the 
chromosome 22qll deletion and overlapping clinical 
features (Driscoll et aI. , 1995). Thus far, several cDNA and 
molecular probes used to diagnose CATCH22, including 
DOS, have been isolated and generated. However, none of 
them encompasses the ADU breakpoint. Therefore, we 
generated a new probe which covers the ADU breakpoint. 
Two oligonucleotide primers, Bland B2, originally 
designed to isolate a critical gene for DOS encompassing 
-the -ADU breakpoint, were designed to be located at both 
the 5' (centromeric) and 3' (telomeric) side of the balanced 
translocation breakpoint (Budarf et aI., 1995), respectively, 
and were chemically synthesized to perform PCR using the 
human genomic DNA as a template (Fig. I). The resulting 
680 bp fragment (DOCR680) was cloned into the EcoRY 
restriction endonuclease site in the pBluescript SK vector 
(pDGCR680), and used as the hybridization probe to 
diagnose DOS among patients having congenital heart 
disease. 
The DNA from the 13 patients and four normal 
controls were completely digested with the restriction 
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Fig. 1. Schematic diagram of 22q II showing relative order of probes. The vertical line indicates the ADD balanced translocation 
breakpoint, and the empty rectangles designate the loci. The black rectangle shows the DGCR680 probe, under which the primers B I 
and B2 are marked. The DiGeorge syndrome critical region (DGCR) is shown by a double-headed arrow above the schematic 
chromosome 22. 
endonuclease, HindIII , and subjected to Southern 
hybridization with DGCR680 as a hybridization probe. 
Surprisingly, the probe hybridized with two specific bands: 
one was the 18 kb fragment located in the DGCR, and the 
other was the unidentified 16 kb fragment. Furthermore, 
the relati ve band intensities of the two bands were the 
same in all four normal controls, whereas in the 13 
patients, the intensities varied consistently, where the 
intensity of the upper band was weaker than the lower 
band . The 16 kb band was located neither in the 
PACl6K23 nor in the PACILlI region (constructed by 
Pieter J. Dejong), which covers about 200 kb around the 
ADU breakpoint (data not shown). A primitive study with 
panel blot hybridization implied that the 16 kb band was 
not from the chromosome 22, although the exact locus was 
not identified. Therefore we regarded the 16 kb band as 
being the internal control of two copies lying outside the 
DGCR. 
Figure 2 shows the Southern blot data where the 
intensity of the 18 kb fragment is not reduced relative to 
that of the 16 kb fragment in normal controls, whereas the 
kb c 2 3 4 5 6 7 8 9 10 11 12 13 
, 
-.. M!' 
• 
Fig. 2. Southern blot analysis of patients having congenital heart 
disease. Normal control (C) and the patient numbers are shown at 
the top. 
relative intensity of the 18 kb fragment was reduced in 
patients 1,3, 4,6, 7, 10, 11 , 12, and 13. The copy number 
of the DGCR locus was determined by the relative band 
intensities quantitated by the PhosphorImager directly on 
the membrane, considering the the 16 kb fragment as a 
diploid control. Since one or two copies of the locus are 
assumed to be present, the dosage was calculated following 
the standard protocol (Driscoll et aI., 1992), in which 
values less than l.5 were considered as heterozygosity (see 
Materials and Methods). As shown in Table 2, 9 out of 13 
patients had monosomy at the chromosomal locus 22q 11. 
Since most patients with DGS are known to be 
associated with a large locus deletion at around 22q 11 , a 
commercial D22S75 DiGeorge chromosome region probe 
was applied to check the monosomy at this locus , mapped 
at about 160 kb from the ADU breakpoint toward the 
telomeric end. Nine patients (patients 1, 4, 6, 7, 8, 9, 10, 
11 , and 12) were randomly chosen and fluorescence in situ 
hybridization (FISH) was individually performed (Fig. 3). 
Surprisingly, the deletions were detected in all nine cases. 
Pat.ients 8 and 9 were particularly interesting since they did 
not have any deletion at the locus DGCR680 whereas the 
locus D22S75 was deleted. Also, both patients did not 
exhibit any typical facial dysmorphism. Furthermore, 
patients 2 and 5, who did not have monosomy at the 
DGCR680 locu s, did not exhibit the typical facial 
dysmorphism either, although the deletion at the D22S75 
locu s was not checked due to the failure of FISH . 
Meanwhile , the patients who had deletions at the 
DGCR680 locus (patients 1,3,6, 7, 10, 11 , 12, and 13) did 
exhibit the typical DGS-type face, such as hypertelorism, 
narrow eye fissures, bloated eyelids, a flat nasal bridge, a 
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Table 2. Summary of dosage analysis of DGS patients by 
quantitati ve hybridization. 
Object number Locus copy numbera 
Patient 1 1.00b 
2 1.58 
3 0.67 
4 0.86b 
5 1.7 1 
6 0.89b 
7 0.38b 
8 2.06b 
9 1.73b 
10 0.43b 
11 0.69b 
12 1.08b 
13 0.98 
Normal 14 2.01 
15 2.01 
16 2.29 
17 1.76 
a Values less than 1.50 are consistent with a deletion (see 
Materials and Methods). 
b Deletion confirmed by FISH. 
Fig. 3. Confirmati on of deleti on with fluorescence in situ 
hybridization (FISH) on the metaphase chromosome using the 
N25 (D22S75) probe. The in ternal control probe (D22S39) are 
shown on the long arms in both of the chromosome 22 while the 
DGS probe (D22S75) is hybrid ized to on ly the norma l 
chromosome 22 (arrowhead). One single hybridi zation signal 
indicates a deleti on of chro mosome 22q 11.2 in one of the 
chromosomes (arrow). 
small mouth, and deformed ear lobe, etc. (Table I ). This 
res ult may imply th at the DGS-type face could be 
associated with the gene located at the DGCR680 locus, 
strictl y di ssecting the complex phenotypic criteria of DGS. 
In one patient (patient 4), however, the face looked normal 
even though the DGCR680 locus was deleted. Although 
the number of patients we analyzed was not sufficient to 
make any conclusion, there co uld s till be o th e r 
mechanism(s) which can overcome the proposed function 
of the gene(s) located at the DGCR680 locus. Most of the 
patients we have analyzed had both deletions, which was 
not surpri sing since most CATCH22 deletions are rather 
large around the DGCR. 
There have been several reports about the DiGeorge 
syndrome that are caused by the different loci, such as the 
deletions at lOp13 (Daw et al. , 1996; Gelb, 1997), 4p16 
and 4p1 3-q1 2 (Gelb, 1997), 17p1 3 (Greenberg et al., 
1988), and outside the shortest region of the deletion 
overlap in 22qll (Kurahashi et al. , 1996). Although it was 
very unlikely, the patients with non-deletions at DGCR680 
could have a mutation occurring at other loci other than 
DGCR, regardless of the deletion at the D22S75 locus. It 
is also possible that a small rearrangement, small deletions 
or point mutation could have occurred in the region of 
DGCR680. 
A ll in all , th e aetio logy of DGS seems to be 
heterogeneous, not involving a single locus. However, the 
680 bp probe encompassing the ADU breakpoint turned 
out to be interesting since it seemed to be able to di ssect 
the complex phenotype caused by the large deletions in 
most patients. Thus far, it has been estimated that the 
minimum prevalence of 22q 11 deletions among birth 
defects was 1/4000- 1/5000, and this deletion seems to be 
involved in at least 5% of newborns with heart defects 
(Wilson et al. , 1994), which occur in approx imately 8 out 
of every 1000 livebirths (Goldmuntz et al. , 1993). DGS, 
YCFS, and CTAFS belonging to the syndro me with 
chromosome 22q 11 deletion and ove rl apping cl ini cal 
features (Driscoll et al. , 1995), have been reported to have 
deleti ons within the chro mosomal region 22q II with 
frequencies of 89%, 81 %, and 84%, respecti vely (Dri scoll 
et al., 1995 ; Matsuoka et al., 1994). The probe we 
generated in thi s study seemed to be a candidate molecular 
marker to distingui sh the specific phenotype, such as fac ial 
features associated with the DiGeorge syndrome. This 
study implies that systemati c approaches with several 
small DNA probes along the DGCR could dissect the 
complex phenotypes associated with CATCH22 and would 
help to isolate the specific gene related to the specific 
phenotype such as cardiac defects, abnormal faces, thymic 
hypoplasia, cleft palate, and hypocalcemia, etc. 
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